Citable filing context

GILD filing events and research context

Server-rendered

GILD's research view summarizes recent SEC filing context, starting with debt_offering from May 20, 2026.

GILD filing events and research context
FiledItemContext
May 20, 2026debt_offeringGilead Sciences issued $3.0 billion in 4.250%, 4.400%, 4.600%, and 4.900% senior notes due 2028, 2029, 2031, and 2034.
May 7, 2026earningsGilead reported Q1 2026 revenue of $7.0 billion and diluted EPS of $1.61, raising full-year guidance.
May 4, 2026material_agreementGilead stockholders approved the amended and restated 2022 Equity Incentive Plan at the annual meeting.
May 7, 2026Guidance: diluted_eps-3.25 to -2.85
May 7, 2026Guidance: gaap_effective_tax_rate-220.00 to -150.00
May 7, 2026Guidance: gaap_effective_tax_rate_excluding_iprd22.00 to 22.00
May 7, 2026mda_quarterlyGilead Sciences reported a 4% increase in total revenues to $6.96 billion and a 54% rise in net income to $2.02 billion for the first quarter of 2026. This growth was primarily driven by strong HIV product sales, with Biktarvy increasing 7% to $3.36 billion and Descovy up 38% to $807 million, alongside a 37% surge in oncology drug Trodelvy sales to $402 million. Conversely, Veklury sales declined 52% to $144 million due to fewer COVID-19 hospitalizations, and Cell Therapy products (Tecartus, Yescarta) saw a 12% decrease amidst competitive headwinds. Product gross margin improved to 79.2%. Post-quarter, Gilead significantly expanded its pipeline through acquisitions, including Arcellx for anito-cel (multiple myeloma, BLA accepted), Tubulis for next-generation antibody-drug conjugates, and Ouro Medicines for OM336 (autoimmune T cell engager). These deals are projected to result in approximately $11.5 billion in acquired in-process research and development expenses in Q2 2026, leading to an expected net loss for both the second quarter and the full year. Operating cash flow increased 45% to $2.54 billion, and $2.75 billion in senior unsecured notes were repaid, though a new $1.1 billion term loan was secured. The company faces ongoing material financial risks from significant litigation, including antitrust lawsuits concerning HIV drugs and product liability claims related to older HIV treatments.
Feb 24, 2026businessGilead Sciences is a biopharmaceutical company with over three decades of innovation, primarily focused on developing medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer, operating in over 35 countries. Its commercial portfolio encompasses over 25 therapies. Key HIV products include Biktarvy, a leading once-daily single-tablet regimen, and Descovy, utilized for both treatment and pre-exposure prophylaxis (PrEP). In liver disease, Epclusa is a significant therapy for chronic HCV, alongside Vemlidy for HBV. Oncology represents a growing area with CAR T-cell therapies like Tecartus (for MCL and ALL) and Yescarta (for LBCL and FL), and Trodelvy for breast cancer. Veklury addresses COVID-19. The company distributes globally through direct teams and third-party wholesalers, with approximately 90% of U.S. gross sales concentrated among Cardinal Health, Cencora, and McKesson. Gilead operates in a highly competitive environment, facing challenges from other pharmaceutical companies, academic institutions, significant pricing pressures from payers, and the introduction of new branded or generic products. Research and development efforts are concentrated on virology, oncology, and inflammation, with substantial outsourcing of clinical trials.

Source: SEC EDGAR filing text and events; period May 20, 2026; filed May 20, 2026.

Continue research

Keep researching GILD

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →